Pharmacokinetics, metabolism, and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans

Drug Metabolism and Disposition

Volumn 36, Issue 11, 2008, Pages 2185-2198

  Dalvie, Deepak ^a,d   Chen, Weichao ^a,b   Zhang, Chenghong ^a,c   Vaz, Alfin D ^a   Smolarek, Teresa A ^a   Cox, Loretta M ^a   Lin, Jian ^a   Obach, R Scott ^a  

^a PFIZER INC   (United States)

^b ARENA PHARMACEUTICALS   (United States)

^c GENENTECH INC   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISTRIFLUOROMETHYLBENZOIC ACID; CYTOCHROME P450 3A; DRUG METABOLITE; QUINALDIC ACID; TORCETRAPIB; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG OXIDATION; DRUG STRUCTURE; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; LIVER MICROSOME METABOLISM; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADOLESCENT; ADULT; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL ESTER TRANSFER PROTEINS; FECES; HUMANS; MALE; MIDDLE AGED; QUINOLINES; TIME FACTORS; YOUNG ADULT;

EID: 54349100968     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.023176     Document Type: Article

References (19)

1. Aventa KM, Riker RR, Fraserb GL, Van der Schyfd CJ, Usuki E, and Pond SM (1997) Metabolism of haloperidol to pyridinium species in patients receiving high doses intravenously: is HPTP an intermediate? Life Sci 61:2383-2390.
2. Borsche W and Manteuffel R (1936) Uber chinolyl-2-brenztraubensaure und chinolyl-2-essigsaure. Ann Chem 526:22-46.
3. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, and Rader DJ (2004) Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350:1505-1515.
4. Clark RW, Ruggeri RB, Cunningham D, and Bamberger MJ (2006) Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res 47:537-552.
5. Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED, Magnus-Aryitey G, Cosgrove PG, Sand TM, Wester RT, Williams JA, et al. (2004) Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multi-dose study in humans. Arterioscler Thromb Vasc Biol 24:490-497.
6. Doering WE and Pasternak VZ (1950) Mechanism of the decarboxylation of α-pyridylacetic acid. J Am Chem Soc 72:143-147.
7. Fang J, McKay G, Song J, Remillrd A, Li X, and Midha K (2001) In vitro characterization of the metabolism of haloperidol using recombinant cytochrome P450 enzymes and human liver microsomes. Drug Metab Dispos 29:1638-1643.
8. Gu C, Collins R, Holsworth DD, Walker GS, and Voorman RL (2006) Metabolic aromatization of N-alkyl-1,2,3,4-tetrahydroquinoline substructures to quinolinium by human liver microsomes and horseradish peroxidase. Drug Metab Dispos 34:2044-2055.
9. Hall LR and Hanzlik RP (1991) N-Dealkylation of tertiary amides by cytochrome P450. Xenobiotica 21:1127-1138.
10. Hamilton RA, Garnett WR, and Kline BJ (1981) Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408-413.
11. Hey J and Tolando R (2000) The oxidation of tertiary amides: mechanistic aspects. J Chem Soc Perkin Trans 2:2328-2336.
12. Howes LG and Kostner K (2007) The withdrawal of torcetrapib from drug development: implications for the future of drugs that alter HDL metabolism. Expert Opin Investig Drugs 16:1509-1516.
13. Khanna R, Morton CL, Danks MK, and Potter PM (2000) Proficient metabolism of irinotecan by a human intestinal carboxylesterase. Cancer Res 60:4725-4728.
14. Labroo RB, Thummel KE, Kunze KL, Podoll T, Trager WF, and Kharasch ED (1995) Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism. Drug Metab Dispos 23:490-496.
15. McKenney JM, Davidson MH, Shear CL, and Revkin JH (2006) Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol 48:1782-1790.
16. Morino A, Nakamura A, Nakanishi K, Tatewaki N, and Sugiyama M (1985) Species differences in the disposition and metabolism of camazepam. Xenobiotica 15:1033-1043.
17. 1H nuclear magnetic resonance. Drug Metab Dispos 36:2064-2079.
18. Quinney SK, Sanghani SP, Davis WI, Hurley TD, Sun Z, Murry DJ, and Bosron WF (2005) Hydrolysis of capecitabine to 5′-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide. J Pharmacol Exp Ther 313:1011-1016.
19. Yumibe N, Huie K, Chen K-J, Snow M, Clement RP, and Cayen MN (1996) Identification of human liver cytochrome P450 enzymes that metabolize the non-sedating antihistamine loratadine. Biochem Pharmacol 51:165-172.